TerminatedPHASE1, PHASE2NCT00555048
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fred Hutchinson Cancer Center
- Principal Investigator
- Ann E. Woolfrey, MDFred Hutchinson Cancer Center
- Intervention
- alemtuzumab(biological)
- Enrollment
- 1 enrolled
- Eligibility
- 50 years · All sexes
- Timeline
- 2007
Study locations (2)
- Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
- Seattle Cancer Care Alliance, Seattle, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00555048 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.